Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Issue 18 (2nd May 2023)

• Record Type: Journal Article
• Authors: Hu, Yuxuan; Wang, Yanning; Shao, Taihang; Tang, Wenxi; Hu, Kerong; Zhou, Yujie; Miao, Liyun; Liu, Jing; Wang, Bin; Yu, Wenying
• Is Part Of: Vaccine. Volume 41:Issue 18(2023)
• Page Start: 3003
• Page End: 3010
• Publication Date: 2023-05-02
• Subjects: COVID-19 -- SARS-CoV-2 -- Heterologous vaccination -- Immunogenicity -- Meta-analysis; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2023.03.056
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens. Materials and methods: We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165. Results: Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety. Discussion: Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety.